Evidence map›Paper›PMID 31097738›Full record

ArticleScientific reports2019

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

A Borrero-Palacios, A Cebrián, M T Gómez Del Pulgar, R García-Carbonero, P Garcia-Alfonso, E Aranda, E Elez, R López-López, A Cervantes, M Valladares and 14 more

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 14 institutions in 2 countries.

A Borrero-PalaciosTranslational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
A CebriánTranslational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain. arancha.cebrian@oncohealth.eu.
M T Gómez Del PulgarTranslational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
R García-CarboneroMedical Oncology Department, Hospital Virgen del Rocío, Sevilla, Spain.
P Garcia-AlfonsoMedical Oncology Department, Hospital Gral. Univ. Gregorio Marañón, Madrid, Spain.
E ArandaMedical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
E ElezMedical Oncology Department, Hospital Vall d'Hebrón, Barcelona, Spain.
R López-LópezMedical Oncology Department, Complexo Hospitalario Universitario Santiago de Compostela, Galicia, Spain.
A CervantesMedical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.ORCID http://orcid.org/0000-0003-3806-3691
M ValladaresMedical Oncology Department, Complejo Hospitalario Universitario A Coruña, Galicia, Spain.
C NadalMedical Oncology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.
J M ViéitezMedical Oncology Department, Hospital Universitario Central de Asturias, Asturias, Spain.
C Guillén-PonceMedical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.ORCID http://orcid.org/0000-0002-3594-1084
J RodríguezMedical Oncology Department, Clínica Universitaria de Navarra, Navarra, Spain.
I HernándezMedical Oncology Department, Complejo Hospitalario de Navarra, Navarra, Spain.
J L GarcíaOncology, Medical Unit, Merck S.L, an affiliate of Merck KGaA, Darmstadt, Germany.
R Vega-BravoAnatomopathology Department, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
A Puime-OtinAnatomopathology Department, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
J Martínez-UserosTranslational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
L Del Puerto-NevadoTranslational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
R RincónTranslational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
M Rodríguez-RemírezTranslational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
F RojoAnatomopathology Department, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
J García-FoncillasTranslational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain. jesus.garciafoncillas@oncohealth.eu.
Hospital Universitario Fundación Jiménez Díaz · ESClinica Universidad de Navarra · ESComplejo Hospitalario de Navarra · ESComplejo Hospitalario Universitario de Santiago · ESComplexo Hospitalario Universitario A Coruña · ESHospital Clínic de Barcelona · ESHospital Clínico Universitario de Valencia · ESHospital General Universitario Gregorio Marañón · ESHospital Universitario Central de Asturias · ESHospital Universitario Ramón y Cajal · ESHospital Universitario Reina Sofía · ESHospital Universitario Virgen del Rocío · ESMerck (Germany) · DEVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.

Identifiers

PMID31097738
PMCPMC6522500
OpenAlexW2945021556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.